Jeffrey D. Buchanan
Analyst · Cai Von Rumohr from Cowen & Company
Thank you, James. Revenue for the quarter was $178.7 million. This is an increase over the prior year of $48.9 million or 37.6%, and well above the high end of our guidance. As James noted, we were at maximum capacity during the fourth quarter. Revenue for the year was $587.5 million; an increase of 42.6% over the prior year. Gross margins continue to rise and were 38.3% in the quarter as compared with 36.1% last year. This is a record gross margin. In fact, excluding the Thompson/Center recall expenses, the gross margins were 40%. This improvement primarily resulted from increased volumes and a planned shift in product mix. Our operating expenses continued to decline as a percentage of revenue. In fact, full year operating expenses have only risen 2% over the prior year, while revenue has risen almost at 43%. In the quarter, operating expenses were $21.6 million or 12.1% of revenue, versus last year's $21.2 million or 16.3% of revenue. We have made a conscious and successful effort to focus on spending less in operating expenses overall. As noted before, however, we do expect to spend more in support of our growth strategy. In fact, we expect our total operating expenses in the first quarter to rise sequentially by 10% to 20%. This leverage of our operating expenses, as well as our focus on achieving efficiencies in manufacturing, have combined to deliver operating income in the fourth quarter at a record level of 26.2% versus 19.8% in the year-ago quarter. For the year, the operating margin was 22.6%, also a record level and more than twice the 10.9% of the prior year. Net income in Q4 is $28.6 million, for a diluted EPS of $0.44, preceding the high end of our expectations by more than 10%. This is compared with net income in the year-ago quarter of $17.8 million, or diluted a EPS of $0.27. Note that during the fourth quarter, we incurred an approximate $3 million of charge for the equivalent impact of $0.03 per diluted share related to the recall. Net income for the year was a record $81.4 million or $1.22 per diluted share compared with net income of $26.4 million or $0.40 per share last year, a more than 3-fold increase. Non-GAAP adjusted EBITDAS in Q4 was $52.7 million compared with $31.2 million in the year-ago period. Our adjusted EBITDAS for the full year totaled $154.2 million, more than twice of fiscal 2012. In the fourth quarter, operating cash flow was $51.3 million and capital spending was $13 million resulting in free cash flow of $38.3 million. For the full year, operating cash flow was $98.1 million and capital spending was $41.4 million resulting in full year free cash flow of $65.2 million, which includes $8.1 million from the sale of discontinued operations. Regarding capital expenditures, we will continue to add capacity and flexibility to service our backlog and to invest in the maintenance and health of our infrastructure and systems, particularly in operations and IT. Thus, we believe, capital expenditures in fiscal '14 will be approximately $40 million to $45 million. At the end of Q4, we had no borrowings under our $60 million credit facility and a cash balance of $100.5 million. The cash-on-hand increased by $44 million versus a year ago driven by strong free cash flow despite buying back 2.1 million shares of our own stock in December for $20 million. As many of you know, we recently announced a series of actions aimed at optimizing our capital structure, increasing our financial flexibility and generating a greater value for our shareholders. Those actions included the following: First, we sold $100 million in the aggregate principal amount of newly issued 5.875% senior notes due in 2017. I would note that although we announced the sale of $75 million of these new notes last week, we have since sold an additional $25 million of the notes. At this point, we do not intend to issue anymore. Second, we repurchased $49.2 million of our 9.5% notes. And third, our Board of Directors approved the repurchase of up to $100 million of our common stock, representing about 50% of our outstanding shares. Up to $75 million of the buyback is planned to occur via a fixed price tender offer at $10 per share, and the remaining balance is planned to occur through open market or private transactions. The $100 million repurchase authorization replaces the prior $15 million authorization. The fixed price from tender is expected to close on July 15. And with that, I'll turn that the call back over to James for discussion of our operational results.